Cilnidipine
Clinical data | |
---|---|
Trade names | Atelec (アテレック), Cilaheart, Cilacar |
AHFS/Drugs.com | International Drug Names |
ATC code | |
Identifiers | |
| |
JSmol) | |
|
Cilnidipine is a calcium channel blocker. Cilnidipine is approved for use in Japan, China, India, Nepal, and Korea for hypertension.
It is a calcium antagonist accompanied with L-type and N-type calcium channel blocking functions. Unlike other calcium antagonists, cilnidipine can act on the N-type calcium channel in addition to acting on the L-type calcium channel.
It was patented in 1984 and approved for medical use in 1995. Cilnidipine is currently being repurposed and developed for use in patients with Raynaud's Phenomenon and Systemic Sclerosis by Aisa Pharma, a US biopharma development company.[1]
Medical uses
Cilnidipine decreases blood pressure and is used to treat hypertension and its
Side effects
The side effects could be severe dizziness, fast heartbeat, and swelling of face, lips, tongue, eyelids, hands and feet. Lesser side effects include stomach pain, diarrhea and hypotension.
Peripheral edema, a common side effect from the use of amlodipine, was reduced when patients were shifted to cilnidipine.[5]
Brand Name
In India, it is sold under the brand name Cinod, cilacar, clinblue, among others at doses of 5mg/10mg/20mg.[6]
History
It was jointly developed by
References
- ISBN 9783527607495.
- PMID 28448181.
- PMID 23339732.
- ^ "ANZCTR - Registration".
- PMID 11136301.
- ^ "Cilacar (Cilnidipine): Uses, Side Effects, Dosage - Medical Dialogues". Medical Dialogues. 3 March 2021. Retrieved 3 March 2021.
Further reading
- Löhn M, Muzzulini U, Essin K, Tsang SY, Kirsch T, Litteral J, et al. (May 2002). "Cilnidipine is a novel slow-acting blocker of vascular L-type calcium channels that does not target protein kinase C". Journal of Hypertension. 20 (5): 885–93. S2CID 30765257.